The role of DNA polymerase η in translesion synthesis past platinum-DNA adducts in human fibroblasts

Cancer Research

Volumn 64, Issue 18, 2004, Pages 6469-6475

  Bassett, Ekaterina ^a,d   King, Nicole M ^a,b   Bryant, Miriam F ^a   Hector, Suzanne ^c   Pendyala, Lakshmi ^c   Chaney, Stephen G ^a,b   Cordeiro Stone, Marila ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA POLYMERASE; GENE PRODUCT; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; OXALIPLATIN; PLATINUM DERIVATIVE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA ADDUCT; DRUG CYTOTOXICITY; FIBROBLAST; GENE; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; HPRT GENE; HUMAN; HUMAN CELL; MUTAGENESIS; MUTAGENICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ULTRAVIOLET C RADIATION; XERODERMA PIGMENTOSUM;

ANTINEOPLASTIC AGENTS; CISPLATIN; DNA; DNA ADDUCTS; DNA-DIRECTED DNA POLYMERASE; FIBROBLASTS; FRAMESHIFT MUTATION; GENE DELETION; HUMANS; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MALE; ORGANOPLATINUM COMPOUNDS; ULTRAVIOLET RAYS; XERODERMA PIGMENTOSUM;

EID: 4644298784     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1328     Document Type: Article

References (50)

1. Greene MH. Is cisplatin a human carcinogen? J Nat Cancer Inst 1992;84:306-12.
2. Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429-39.
3. Leopold WR, Batzinger RP, Miller EC, Miller JA, Earhardt RH. Mutagenicity, tumorigenicity, and electrophilic reactivity of the stereoisomeric platinum(II) complexes of 1,2-diaminocyclohexane. Cancer Res 1981;41:4368-77.
4. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 1987;34:155-66.
5. Burnouf D, Daune M, Fuchs RP. Spectrum of cisplatin-induced mutations in Escherichia coli. Proc Natl Acad Sci USA 1987;84:3758-62.
6. Bubley GJ, Ashburner BP, Teicher BA. Spectrum of cis- diamminedichloroplatinum(II)-induced mutations in a shuttle vector propagated in human cells. Mol Carcinog 1991;4:397-406.
7. Vaisman A, Varchenko M, Umar A, et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 1998;58:3579-85.
8. Gibbons GR, Kaufmann WK, Chaney SG. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells. Carcinogenesis 1991;12:2253-7.
9. Villani G, Hubscher U, Butour JL. Sites of termination of in vitro DNA synthesis on cis-diamminedichloroplatinum(II) treated single-stranded DNA: a comparison between E. coli DNA polymerase I and eukaryotic DNA polymerase alpha. Nucl Acid Res 1988;16:4407-18.
10. Hoffmann JS, Pillaire MJ, Maga G, Podust V, Hubscher U, Villani G. DNA polymerase beta bypasses in vitro a single d(GpG)-cisplatin adduct placed on codon 13 of the HRAS gene. Proc Natl Acad Sci USA 1995;92:5356-60.
11. Burgers PM, Koonin EV, Bruford E, et al. Eukaryotic DNA polymerases: proposal for a revised nomenclature. J Biol Chem 2001;276:43487-90.
12. Bebenek K, Kunkel TA. Family growth: the eukaryotic DNA polymerase revolution. Cell Mol Life Sci 2002;59:54-7.
13. Lehmann AR. Replication of damaged DNA in mammalian cells: new solutions to an old problem. Mutat Res 2002;509:23-34.
14. McDonald JP, Tissier A, Frank EG, Iwai S, Hanaoka F, Woodgate R. DNA polymerase iota and related Rad30-like enzymes. Phil Trans R Soc Lond B Biol Sci 2001;356:53-60.
15. Ohashi E, Ogi T, Kusumoto R, et al. Error-prone bypass of certain DNA lesions by the human DNA polymerase kappa. Genes Dev 2000;14:1589-94.
16. Maga G, Villani G, Ramadan K, et al. Human DNA polymerase lambda functionally and physically interacts with proliferating cell nuclear antigen in normal and translesion DNA synthesis. J Biol Chem 2002;277:48434-40.
17. Vaisman A, Lim SE, Patrick SM, et al. Effect of DNA polymerases and high mobility group protein I on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. Biochemistry 1999;38:11026-39.
18. Vaisman A, Masutani C, Hanaoka F, Chaney SG. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. Biochemistry 2000;39:4575-80.
19. Vaisman A, Chaney SG. The efficiency and fidelity of translesion synthesis past cisplatin and oxaliplatin GpG adducts by human DNA polymerase beta. J Biol Chem 2000;275:13017-25.
20. Johnson RE, Prakash S, Prakash L. Requirement of DNA polymerase activity of yeast Rad30 protein for its biological function. J Biol Chem 1999;274:15975-7.
21. Masutani C, Kusumoto R, Yamada A, et al. The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. Nature 1999;399:700-4.
22. Roush AA, Suarez M, Friedberg EC, Radman M, Siede W. Deletion of the Saccharomyces cerevisiae gene RAD30 encoding an Escherichia coli DinB homolog confers UV radiation sensitivity and altered mutability. Mol Gen Genet 1998;257:686-92.
23. Grossmann KF, Ward AM, Matkovic ME, Folias AE, Moses RE. S. cerevisiae has three pathways for DNA interstrand crosslink repair. Mutat Res 2001;487:73-83.
24. Masutani C, Araki M, Yamada A, et al. Xeroderma pigmentosum variant (XP-V) correcting protein from HeLa cells has a thymine dimer bypass DNA polymerase activity. EMBO J 1999;18:3491-501.
25. Johnson RE, Kondratick CM, Prakash S, Prakash L. hRAD30 mutations in the variant form of xeroderma pigmentosum. Science 1999;285:263-5.
26. Masutani C, Kusumoto R, Iwai S, Hanaoka F. Mechanisms of accurate translesion synthesis by human DNA polymerase eta. EMBO J 2000;19:3100-9.
27. Yamada K, Takezawa J, Ezaki O. Translesion replication in cisplatin-treated xeroderma pigmentosum variant cells is also caffeine-sensitive: features of the error-prone DNA polymerase(s) involved in UV-mutagenesis. DNA Repair (Amst) 2003;2:909-24.
28. Maher VM, McCormick JJ. The HPRT gene as a model system for mutation analysis. In: Pfeifer GP, editor. Technologies for detection of DNA damage and mutations. New York: Plenum Press; 1996. pp. 381-90.
29. Boyer JC, Kaufmann WK, Cordeiro-Stone M. Role of postreplication repair in transformation of human fibroblasts to anchorage independence. Cancer Res 1991;51:2960-4.
30. Heffernan TP, Simpson DA, Frank AR, et al. An ATR- and Chk1-dependent S checkpoint inhibits replicon initiation following UVC-induced DNA damage. Mol Cell Biol 2002;22:8552-61.
31. Ouellette MM, McDaniel LD, Wright WE, Shay JW, Schultz RA. The establishment of telomerase-immortalized cell lines representing human chromosome instability syndromes. Hum Mol Genet 2000;9:403-11.
32. Cordeiro-Stone M, Frank A, Bryant M, et al. DNA damage responses protect xeroderma pigmentosum variant from UVC-induced clastogenesis. Carcinogenesis 2002;23:959-65.
33. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 2001;48:398-406.
34. Maher VM, Ouellette LM, Curren RD, McCormick JJ. Frequency of ultraviolet light-induced mutations is higher in xeroderma pigmentosum variant cells than in normal human cells. Nature 1976;261:593-5.
35. Myhr BC, Turnbull D, DiPaolo JA. Ultraviolet mutagenesis of normal and xeroderma pigmentosum variant human fibroblasts. Mutat Res 1979;62:341-53.
36. Boyer JC, Kaufmann WK, Brylawski BP, Cordeiro-Stone M. Defective post-replication repair in xeroderma pigmentosum variant fibroblasts. Cancer Res 1990;50:2593-8.
37. Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P, Harrap KR. Ammine/amine platinum(IV) dicarboxylates - a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 1992;52:822-8.
38. Havener JM, McElhinny SA, Bassett E, Gauger M, Ramsden DA, Chaney SG. Translesion synthesis past platinum DNA adducts by human DNA polymerase μ. Biochemistry 2003;42:1777-88.
39. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-79.
40. Stadler VM, Hayden A, von der Maase H, et al. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 2002;7:153-7.
41. Sabbatini P, Aghajanian C, Leitao M, et al. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II trial. Clin Cancer Res 2004;10:2962-7.
42. Correale P, Messinese S, Caraglia M, et al. A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. Br J Cancer 2004. Epub 2004 Apr 13.
43. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110-7.
44. Bresson A, Fuchs RP. Lesion bypass in yeast cells: pol eta participates in a multi-DNA polymerase process. EMBO J 2002;21:3881-7.
45. Bassett E, Vaisman A, Havener JM, Masutani C, Hanaoka F, Chaney SG. Efficiency of extension of mismatched primer termini across from cisplatin and oxaliplatin adducts by human DNA polymerases beta and eta in vitro. Biochemistry 2003;42:14197-206.
46. Mitchell DL, Nairn RS. The biology of the (6-4) photoproduct. Photochem Photobiol 1989;49:805-19.
47. Kannouche P, Stary A. Xeroderma pigmentosum variant and error-prone DNA polymerases. Biochimie 2003;85:1123-32.
48. Eastman A. Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II). Biochemistry 1983;22:3927-33.
49. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 1985;24:707-13.
50. Lin X, Ramamurthi K, Mishima M, Kondo A, Christen RD, Howell SB. P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res 2001;61:1508-16.